These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 20952483

  • 1. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
    Agarwal S, Sane R, Ohlfest JR, Elmquist WF.
    J Pharmacol Exp Ther; 2011 Jan; 336(1):223-33. PubMed ID: 20952483
    [Abstract] [Full Text] [Related]

  • 2. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
    Agarwal S, Elmquist WF.
    Mol Pharm; 2012 Mar 05; 9(3):678-84. PubMed ID: 22335402
    [Abstract] [Full Text] [Related]

  • 3. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF.
    J Pharmacol Exp Ther; 2010 Jul 05; 334(1):147-55. PubMed ID: 20421331
    [Abstract] [Full Text] [Related]

  • 4. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R, Agarwal S, Mittapalli RK, Elmquist WF.
    J Pharmacol Exp Ther; 2013 Apr 05; 345(1):111-24. PubMed ID: 23397054
    [Abstract] [Full Text] [Related]

  • 5. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
    Wang T, Agarwal S, Elmquist WF.
    J Pharmacol Exp Ther; 2012 May 05; 341(2):386-95. PubMed ID: 22323823
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O.
    Clin Cancer Res; 2007 Nov 01; 13(21):6440-9. PubMed ID: 17975156
    [Abstract] [Full Text] [Related]

  • 7. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF.
    Cancer Res; 2009 Jul 15; 69(14):5885-92. PubMed ID: 19567673
    [Abstract] [Full Text] [Related]

  • 8. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2013 Oct 15; 76():9-16. PubMed ID: 23827160
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
    Oberoi RK, Mittapalli RK, Elmquist WF.
    J Pharmacol Exp Ther; 2013 Dec 15; 347(3):755-64. PubMed ID: 24113148
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF.
    J Pharmacol Exp Ther; 2012 Jul 15; 342(1):33-40. PubMed ID: 22454535
    [Abstract] [Full Text] [Related]

  • 12. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y.
    J Pharmacol Exp Ther; 2010 Jun 15; 333(3):788-96. PubMed ID: 20304939
    [Abstract] [Full Text] [Related]

  • 13. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S, Camenisch G, Lemaire M, Scherrmann JM.
    J Neurochem; 2007 Sep 15; 102(6):1749-1757. PubMed ID: 17696988
    [Abstract] [Full Text] [Related]

  • 14. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M, Khurana V, Qin B, Pal D, Mitra AK.
    Int J Pharm; 2012 Sep 15; 434(1-2):306-14. PubMed ID: 22633931
    [Abstract] [Full Text] [Related]

  • 15. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF.
    J Pharmacol Exp Ther; 2009 Sep 15; 330(3):956-63. PubMed ID: 19491323
    [Abstract] [Full Text] [Related]

  • 16. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.
    Mol Cancer Ther; 2008 Aug 15; 7(8):2280-7. PubMed ID: 18723475
    [Abstract] [Full Text] [Related]

  • 17. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K, Wanek T, Bankstahl M, Bankstahl JP, Fedrowitz M, Müller M, Löscher W, Kuntner C, Langer O.
    Nucl Med Biol; 2013 Oct 15; 40(7):873-8. PubMed ID: 23845421
    [Abstract] [Full Text] [Related]

  • 18. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
    de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O.
    Invest New Drugs; 2012 Apr 15; 30(2):443-9. PubMed ID: 20963470
    [Abstract] [Full Text] [Related]

  • 19. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y.
    J Pharmacol Exp Ther; 2011 Dec 15; 339(3):935-44. PubMed ID: 21934030
    [Abstract] [Full Text] [Related]

  • 20. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ, Milton MN, Yu S, Liao M, Liu N, Wu JT, Gan L, Balani SK, Lee FW, Prakash S, Xia CQ.
    Drug Metab Lett; 2010 Dec 15; 4(4):201-12. PubMed ID: 20670210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.